- Previous Close
2,300.00 - Open
2,320.00 - Bid 2,440.00 x --
- Ask 2,460.00 x --
- Day's Range
2,310.00 - 2,460.00 - 52 Week Range
1,500.00 - 2,500.00 - Volume
198,210 - Avg. Volume
105,635 - Market Cap (intraday)
103.185B - Beta (5Y Monthly) 0.01
- PE Ratio (TTM)
-- - EPS (TTM)
-260.76 - Earnings Date Nov 7, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. The company is based in Zug, Switzerland.
oculis.comRecent News: OCS.IC
View MorePerformance Overview: OCS.IC
Trailing total returns as of 12/13/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: OCS.IC
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: OCS.IC
View MoreValuation Measures
Market Cap
101.01B
Enterprise Value
84.55B
Trailing P/E
62.00
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
6.86
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-33.46%
Return on Equity (ttm)
-69.33%
Revenue (ttm)
868k
Net Income Avi to Common (ttm)
-69.62M
Diluted EPS (ttm)
-260.76
Balance Sheet and Cash Flow
Total Cash (mrq)
105.47M
Total Debt/Equity (mrq)
1.30%
Levered Free Cash Flow (ttm)
-26.35M